Abigail Hall
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Abigail Hall has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Nathan Alves Neres
Department of Emergency Medicine Indiana University School of Medicine Indianapolis Indiana USA
3 shared publications - Alexei Christodoulides
Department of Emergency Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA
1 shared publication - Andres Prieto Trujillo
Department of Emergency Medicine, Indiana University School of Medicine, 635 Barnhill Dr. Rm. 2063, Indianapolis, IN 46202, USA
1 shared publication - Anushri Umesh
Department of Emergency Medicine, Indiana University School of Medicine, 635 Barnhill Dr. Rm. 2063, Indianapolis, IN 46202, USA
1 shared publication - Daniela Q. Tran
Department of Emergency Medicine, Indiana University School of Medicine, Indiana University, Indianapolis, IN 46202, USA
1 shared publication - Kennedy Helms
Department of Emergency Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA
1 shared publication
Latest Publications
- Open Access
- 26 June 2026
- Published by MDPI AG in Biomolecules
- Vol. 16 (7) , 949
Real-Time Fibrinolysis Monitoring of Plasma Annular Clots
Fibrinolysis assessment is critical for diagnosing and managing clinical blood disorders. Currently available viscoelastic testing platforms provide an overview of global coagulation and fibrinolysis profiles but lack fibrinolysis specific assessment of a preformed clot substrate. The lack of a sensitive, standardized testing platform for fibrinolysis assessment can limit risk stratification and the management of blood disorders. We describe herein the plasma annular clot lysis assay. The assay adapts the previously standardized FITC-tagged fibrin annular clot assay to plasma obtained from healthy human donors. Plasmin at concentrations ranging from 200–800 nM was used as a direct thrombolytic to assess fibrinolysis in plasma-derived annular clots. The Maximum Fibrinolysis Rate (VMFR), FLU200, T90, and MaxFLU were calculated via tracking of the clot digestion curve over time. VMFR was correlated with plasma thromboelastography (TEG) parameters to compare with the global viscoelastic testing system. Additionally, plasma annular clot digestion was monitored in the presence of pentamidine to assess drug-specific effects on fibrinolysis tracking. Plasma annular clots linearly tracked fibrinolysis with increasing plasmin concentration. VMFR across multiple tested plasmin concentrations showed a moderate to strong negative correlation (0.58–0.74) with the observed maximum amplitude from plasma TEG. In the presence of pentamidine (75 µM), the assay was sensitive to identifying differences in the VMFR across treatment groups. Plasma annular clots provide a platform for fibrinolysis evaluation using a patient’s own plasma to assess therapeutic dosing clinically in addition to testing novel therapeutics preclinically to further understand mechanistic aspects of fibrinolysis.
- 26 June 2026
- Published by MDPI AG in Biomolecules
- Vol. 16 (7) , 949
Open AccessReal-Time Fibrinolysis Monitoring of Plasma Annular Clots
Fibrinolysis assessment is critical for diagnosing and managing clinical blood disorders. Currently available viscoelastic testing platforms provide an overview of global coagulation and fibrinolysis profiles but lack fibrinolysis specific assessment of a preformed clot substrate. The lack of a sensitive, standardized testing platform for fibrinolysis assessment can limit risk stratification and the management of blood disorders. We describe herein the plasma annular clot lysis assay. The assay adapts the previously standardized FITC-tagged fibrin annular clot assay to plasma obtained from healthy human donors. Plasmin at concentrations ranging from 200–800 nM was used as a direct thrombolytic to assess fibrinolysis in plasma-derived annular clots. The Maximum Fibrinolysis Rate (VMFR), FLU200, T90, and MaxFLU were calculated via tracking of the clot digestion curve over time. VMFR was correlated with plasma thromboelastography (TEG) parameters to compare with the global viscoelastic testing system. Additionally, plasma annular clot digestion was monitored in the presence of pentamidine to assess drug-specific effects on fibrinolysis tracking. Plasma annular clots linearly tracked fibrinolysis with increasing plasmin concentration. VMFR across multiple tested plasmin concentrations showed a moderate to strong negative correlation (0.58–0.74) with the observed maximum amplitude from plasma TEG. In the presence of pentamidine (75 µM), the assay was sensitive to identifying differences in the VMFR across treatment groups. Plasma annular clots provide a platform for fibrinolysis evaluation using a patient’s own plasma to assess therapeutic dosing clinically in addition to testing novel therapeutics preclinically to further understand mechanistic aspects of fibrinolysis.
- Open Access
- 21 August 2024
- Published by MDPI AG in Environments
- Vol. 11 (8) , 180
Microplastic and Nanoplastic Particle Isolation from Liquid and Biological Samples via Mini-Extruder Filtration (MEF)
Microplastic pollution poses an increasing environmental and human health risk and additional techniques are needed to facilitate nondestructive, quantitative particle recovery and analysis. Using a mini-extruder filtration (MEF) device, the efficiency of pristine particle capture from solution and digested biological tissue (blood clots) was assessed. Polystyrene particles in both the submicron (100, 300, and 500 nm) and micron range (2, 5, 7, and 10 µm) with aminated, carboxylated, or unmodified surface modifications were explored. The MEF-isolated-particle recovery was analyzed pre- and postseparation isolation and quantified via a Nanosight LM10 particle tracking system (submicron particles) or hemacytometer (micron particles). Particles’ surface chemistry and concentration did not impact recovery compared to unfiltered samples with smaller particle sizes reducing recovery efficiency. Micron particle size recovery averaged 86.8 ± 4.3% across all surface chemistries at the same concentration; however, submicron particle recoveries varied by size and charge with 500 nm exhibiting recoveries of 80.6 ± 16.6%, 300 nm 73.0 ± 10.4%, and 100 nm particles 17.0 ± 10.3%. The mini-extruder device, used as a filtration recovery system, efficiently captures 10 to 0.5 µm particles from environmental and tissue samples making it an effective and low-cost platform facilitating the nondestructive capture of diverse microplastics for subsequent analysis.
- 21 August 2024
- Published by MDPI AG in Environments
- Vol. 11 (8) , 180
Open AccessMicroplastic and Nanoplastic Particle Isolation from Liquid and Biological Samples via Mini-Extruder Filtration (MEF)
Microplastic pollution poses an increasing environmental and human health risk and additional techniques are needed to facilitate nondestructive, quantitative particle recovery and analysis. Using a mini-extruder filtration (MEF) device, the efficiency of pristine particle capture from solution and digested biological tissue (blood clots) was assessed. Polystyrene particles in both the submicron (100, 300, and 500 nm) and micron range (2, 5, 7, and 10 µm) with aminated, carboxylated, or unmodified surface modifications were explored. The MEF-isolated-particle recovery was analyzed pre- and postseparation isolation and quantified via a Nanosight LM10 particle tracking system (submicron particles) or hemacytometer (micron particles). Particles’ surface chemistry and concentration did not impact recovery compared to unfiltered samples with smaller particle sizes reducing recovery efficiency. Micron particle size recovery averaged 86.8 ± 4.3% across all surface chemistries at the same concentration; however, submicron particle recoveries varied by size and charge with 500 nm exhibiting recoveries of 80.6 ± 16.6%, 300 nm 73.0 ± 10.4%, and 100 nm particles 17.0 ± 10.3%. The mini-extruder device, used as a filtration recovery system, efficiently captures 10 to 0.5 µm particles from environmental and tissue samples making it an effective and low-cost platform facilitating the nondestructive capture of diverse microplastics for subsequent analysis.
- Open Access
- 13 December 2022
- Published by MDPI AG in Biomolecules
- Vol. 12 (12) , 1864
Microplastic Effects on Thrombin–Fibrinogen Clotting Dynamics Measured via Turbidity and Thromboelastography
Micro/nanoplastics, whether manufactured or resulting from environmental degradation, can enter the body through ingestion, inhalation, or dermal pathways. Previous research has found that nanoplastics with diameters of ≤100 nm can translocate into the circulatory system in a dose-dependent manner and potentially impact thrombosis and hemostasis. To investigate the direct effects of microplastics on fibrin clot formation, a simplified ex vivo human thrombin/fibrinogen clot model was utilized. The 100 nm polystyrene particles (non-functionalized [nPS] and aminated [aPS]) were preincubated (0–200 µg/mL) with either thrombin or fibrinogen, and fibrin clot formation was characterized via turbidity and thromboelastography (TEG). When the particles were preincubated with fibrinogen, little effect was observed for aPS or nPS on turbidity or TEG up through 100 µg/mL. TEG results demonstrated a significant impact on clot formation rate and strength, in the case of nPS preincubated with thrombin exhibiting a significant dose-dependent inhibitory effect. In conclusion, the presence of microplastics can have inhibitory effects on fibrin clot formation that are dependent upon both particle surface charge and concentration. Negatively charged nPS exhibited the most significant impacts to clot strength, turbidity, and rate of fibrin formation when first incubated with thrombin, with its impact being greatly diminished when preincubated with fibrinogen in this simplified fibrin clot model.
- 13 December 2022
- Published by MDPI AG in Biomolecules
- Vol. 12 (12) , 1864
Open AccessMicroplastic Effects on Thrombin–Fibrinogen Clotting Dynamics Measured via Turbidity and Thromboelastography
Micro/nanoplastics, whether manufactured or resulting from environmental degradation, can enter the body through ingestion, inhalation, or dermal pathways. Previous research has found that nanoplastics with diameters of ≤100 nm can translocate into the circulatory system in a dose-dependent manner and potentially impact thrombosis and hemostasis. To investigate the direct effects of microplastics on fibrin clot formation, a simplified ex vivo human thrombin/fibrinogen clot model was utilized. The 100 nm polystyrene particles (non-functionalized [nPS] and aminated [aPS]) were preincubated (0–200 µg/mL) with either thrombin or fibrinogen, and fibrin clot formation was characterized via turbidity and thromboelastography (TEG). When the particles were preincubated with fibrinogen, little effect was observed for aPS or nPS on turbidity or TEG up through 100 µg/mL. TEG results demonstrated a significant impact on clot formation rate and strength, in the case of nPS preincubated with thrombin exhibiting a significant dose-dependent inhibitory effect. In conclusion, the presence of microplastics can have inhibitory effects on fibrin clot formation that are dependent upon both particle surface charge and concentration. Negatively charged nPS exhibited the most significant impacts to clot strength, turbidity, and rate of fibrin formation when first incubated with thrombin, with its impact being greatly diminished when preincubated with fibrinogen in this simplified fibrin clot model.